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Abstract
Background: High throughput molecular sequencing and increased biospecimen variety have introduced
significant informatics challenges for research biorepository infrastructures. We applied a modular system
integration approach to develop an operational biorepository management system. This method enables
aggregation of the clinical, specimen and genomic data collected for biorepository resources.
Methods: We introduce an electronic Honest Broker (eHB) and Biorepository Portal (BRP) open source project
that, in tandem, allow for data integration while protecting patient privacy. This modular approach allows
data and specimens to be associated with a biorepository subject at any time point asynchronously. This
lowers the bar to develop new research projects based on scientific merit without institutional review for
a proposal.
Results: By facilitating the automated de-identification of specimen and associated clinical and genomic
data we create a future proofed specimen set that can withstand new workflows and be connected to new
associated information over time. Thus facilitating collaborative advanced genomic and tissue research.
Conclusions: As of Janurary of 2016 there are 23 unique protocols/patient cohorts being managed in the
Biorepository Portal (BRP). There are over 4000 unique subject records in the electronic honest broker (eHB),
over 30,000 specimens accessioned and 8 institutions participating in various biobanking activities using this
tool kit. We specifically set out to build rich annotation of biospecimens with longitudinal clinical data; BRP/REDCap
integration for multi-institutional repositories; EMR integration; further annotated specimens with genomic data specific
to a domain; build application hooks for experiments at the specimen level integrated with analytic software; while
protecting privacy per the Office of Civil Rights (OCR) and HIPAA.
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Background
Current research is yielding rapid advances in personal-
ized, precision medicine through targeted therapies
based on an individual’s genome, genomic biomarkers,
and cell biology across adult and pediatric translational
research [1, 2]. This type of research has become in-
creasingly dependent on the collection of large cohorts
of high quality human biospecimens that are paired with
clinical annotations [3]. While biospecimen-driven re-
search is widely practiced, it is often limited in scope be-
cause it requires time-consuming manual processes such
as retrospective annotation, cohort identification and in-
stitutional human subjects research oversight [4]. Conse-
quently, many academic medical centers are creating
large institutional biospecimen resources that can be lev-
eraged by numerous investigators [5]. There is a trend
towards these resources becoming indispensable in aca-
demic medical centers [3, 6].
Biorepository data is typically captured in longitudinal,
asynchronous workflows that pose software design and
data integration challenges [7]. An optimal system must
provide de-identified, granular and longitudinal data to
researchers while also enabling data collection workflows
that require patient identification [8]. The required data
often resides in separate systems such as a Laboratory
Information Management System (LIMS), Research Data
Capture tools, the Electronic Health Record (EHR),
genomic data stores and high performance computing
clusters [9, 10]. Integrative solutions are necessary at the
point of collection and at information and specimen re-
trieval. The data must be curated to ensure it is persisted
in an understandable representation for researchers in a
specific medical domain [11, 12]. As biorepository re-
sources include more clinical information and grow
in scale, there are more opportunities for protected
health information (PHI) to be injected into the
process [13, 14]. Therefore, a central component to
this toolkit is an informatics-based approach to hon-
est brokering [15]. We build on methods described in
Dhir et al. and Boyd et al. that describe specific
implementations of software to aid in the honest bro-
kering between various types of clinical data collec-
tion and de-identified biorepositories [14, 16]. We
take a slightly different approach by creating non-user
facing software service similar to Boyd, et al. for the
honest broker as one of many components of a tool-
kit of connected operational biorespository informat-
ics resources. We remove the human component
completely from the de-identification and re-
identification of research records in connected re-
search systems.
In this paper, we address the creation of a robust bior-
epository management platform that enables association
of a physical biospecimens, clinical diagnoses, and
patient, genomic and research. This platform utilizes a
modular software architecture developed at the Chil-
dren’s Hospital of Philadelphia (CHOP) in partnership
with the Children’s Brain Tumor Tissue Consortium
(CBTTC) [17]. The platform was developed in the spe-
cific context of distributed biorepository and biobank
studies in biological tissue and genomic research. In this
manuscript, we describe the requirements, challenges in
architectural design and implementation to create inte-
grated data resources in biospecimen-driven translational
research. We designed and utilized an open source, modu-
lar software toolkit that supports biorepository operations
and de-identified secondary usage. We created an oper-
ational and scientific resource that protects subject priv-
acy, allows for variable specimen and data management
workflows and flexible resource queries. When new sys-
tems and workflows are introduced, the toolkit allows for
flexible introduction of new data types, systems and oper-
ational workflows spanning specimen, clinical, imaging
and genomic data. Our platform allows for extensible soft-
ware and data resources for biospecimen-driven transla-
tional research.
Cancer focus
Cancer is a main focus of current precision medicine ini-
tiatives. This is reflected in politics, the media, public
funding and medical research community priorities [18].
We are in an age of increased use of web technologies
that allow us to reach new levels of productivity and
connectivity in business, finance, government and enter-
tainment [19]. The time has come for us to use these
same techniques to unravel the complexities of cancer
[20]. New breakthroughs are helping us use our own im-
mune systems to target an increasing list of common
cancers [21]. Unfortunetely, time is not on the side of
children suffering from rare brain tumors. Recent re-
search and government population health programs
identify over 120 types of pediatric brain cancers [22].
To make matters more complex, the origins of brain
tumors in kids is widely unknown [22–25]. Pediatric
cancer patients are treated for cancers with adult-
based therapies and there is a lack of investment
from pharmaceutical companies in the specific dis-
eases affecting children [26]. It is essential to create
biologic- and data-centric resources to find pathways
and molecularly describe disease seen in research
similar to Bastianos et al. and Parsons et al. where
developments, respectively, uncover a molecular path-
way in Craniopharyngiomas and a comprehensive mo-
lecular description of the common childhood brain
tumor, Medulloblastoma [27, 28]. Though molecularly
based research has become common with the avail-
ability of high throughput technologies, further pro-
gress is needed in infrastructure, specifically in cancer
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research, that allows for complete clinical annotation
of specimen and genomic data from consented sub-
jects ([29], p. 549).
Initial research of rare tumors at CHOP brought biore-
pository data sharing, management, and annotation is-
sues to the forefront. A need for enhanced capabilities
was particularly evident in two proposed studies targeted
by our initial software system design. These tumor bior-
epository studies originally used a human honest broker
to manage the de-identification and re-identification of
records to exclude protected patient information (a/k/a
patient health information) from the research LIMS. The
process began with manual data intake by a data man-
ager on hardcopy REDCap case report forms (CRFs)
[30]. The CRFs contained the patient identifiers: Medical
Record Number (MRN), First Name, Last Name and
Date of Birth. The CRF was physically delivered to a hu-
man honest broker that would create a new electronic
REDCap record with a research identifier. The hardcopy
CRF was then returned to the data manager with the
research identifier attached and the patient identifiers
removed. The data manager then abstracted the hand
written CRFs to the associated REDCap project record.
Each longitudinal data collection event required manual
re-identification by the human honest broker. This
process became unsustainable as biospecimen and clin-
ical data collection increased and molecular experimen-
tation associated with records began. It was also difficult
to complete the CRF in a single patient encounter due
to variations in encounter length and frequency. This
experience clearly illustrated the need for a scalable
solution that would abide by NCI Best Practices for
Biospecimen Resources [15]. The Biorepository Portal
Toolkit (BRP Toolkit) project was subsequently devel-




We took a modular and entity-driven integrated systems
approach to facilitate variable specimen acquisition and
data collection events. The primary entity is the patient
enrolled as a research subject on the study. The subject
entity is created in the electronic honest broker (eHB)
and assoicated with a master patient index (MPI) and
the subject’s instutional origin. Each external research
record associated with the subject record, in this case
the data management tool, REDCap, is not limited to a
one-to-one relation of subject-to-REDCap record. The
subject entity can be assoicated with many projects,
forms and records in a 1-to-many entity relationaship
[31]. We, in tandem, built a research portal, dubbed the
Biorepository Portal (BRP). The BRP can access subject
records in the electronic Honest Broker (eHB) and
subsequent external research records through token-
based authorization from that client system. The BRP
reproduces the REDCap electronic Case Report Forms
(eCRFs) based on records stored in the eHB with a cus-
tom REDCap client utilizing the REDCap application
programing interface (API), in real-time. This produces
a complete form for that subject at time of access. It dis-
plays the subject information and identifiers at the top
of the screen at all times during form data entry and
while shifting from form to form. A research coordinator
or data manager can enter any temporal and longitu-
dinal research data based on their protocol subject list at
anytime or in any order (i.e., asynchronously) while
maintaining the continuous de-identification and re-
identification of research data automatically.
The CHOP Biorepository Core Facility utilizes Ther-
moFisher Nautilus as its LIMS. As part of our method,
we also built a client to this LIMS that allows for associ-
ation of an arbitrary number of specimen records in the
LIMS with the corresponding subject record. In this way
specimens can also be collected longitudinally over time.
Data and specimen coordinators have the ability to asso-
ciate sets of specimens with a subject or event and anno-
tate that specimen on the fly in one system. For
downstream integration, we use the same eHB software
service to perform our Extract Transform Load (ETL)
processes that are tailored to each project. The result is
a regularly updated non-human subject research data-
base that allows for seamless queries spanning research
and clinical data sets. We allow collaborators to access
specific sets of data via the data exploration tool, Har-
vest [32], customized for each project. The phenotypic
data associated with specimen records can be integrated
with direct clinical data from the EHR with appropriate
institutional permissions. The modular approach allows
us to integrate genomic visualization tools at the speci-
men level where applicable. For cancer genomics specif-
ically, we utilize the CBioPortal [33, 34], an open source
tool to visualize mutation and gene expression data from
The Cancer Genome Atlas (TCGA).
Web service oriented architecture
The integration of tools is accomplished by taking ad-
vantage of modern web technologies. Our methods are
rooted in web service oriented architecture (SOA). This
pattern pervades the current generation of computing
and web technology and is rapidly expanding through
virtual resources accessed via network resources (i.e.,
cloud computing) [35]. We created a plug-and-play
experience working with multiple tools in a web environ-
ment. We employ REST (Representational State Transfer)
API architecture over HTTP protocols providing uniform
channels for applications integrated into the tool kit [36].
In this section, we describe each specific technology in the
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stack, each with its own set of RESTful end-points that
allow us to guide users through multiple tools as they
interact with biorepository resources. Though SOAs are
widely used in the field of biomedical informatics to build
complex application tool chains, they are not transparent
as to their usage and sometimes have very poor adoption
because of their complexity [37]. To address this, we mask
technical complexity with end-user tools that are familiar
Fig. 1 Three workflow iterations. Iterations of the introduction of the modular tool kit from human intervention, electronic intervention to fully
realized modular approach
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to research coordinators, specimen coordinators and data
managers. There is wide recognition that there is no com-
pliant Health Level Seven (HL7)-type interoperability
standards when using SOA’s [9]. The operational applica-
tions and scientific applications we implemented utilize an
honest broker software service, a well-known method of
dealing with de-identification in biorepository research
that maintain the HIPAA compliance in downstream sys-
tems [14, 38–41]. Figure 1 illustrates a high-level architec-
ture description along with external integration points for
key scientific and clinically relevant data points for data
entry and reuse. This figure is split into three parts, the
last of which describes the fully realized modular approach
integrating both clinical, genomic and research specimen
resources.
Electronic Honest Broker (eHB) software service
The concept of an honest broker has been implemented
in other academic medical center environments to pro-
tect privacy when integrating research data ([14, 42], pp.
56–107). Central to our solution is the eHB, a web-
based software service with end-to-end encryption that
maintains an index of subjects linked to their associated
research records. The initial studies/projects targeted
with this solution began as a manual paper-based
process of considerable complexity, and are now an “in-
formatics tool” [15]. The index in the eHB uniquely
identifies each patient through a combination of
organizational association (e.g., The Children’s Hospital
of Philadelphia) and a unique organization provided
identifier (e.g., Medical Record Number). The eHB asso-
ciates each subject record with trusted external systems
and known record identifiers in those systems. For an-
notated biorepository studies, the eHB maintains associ-
ations to de-identified records in REDCap and the
LIMS. Following our SOA approach, the eHB makes
data and system functionality available via a REST web
service. This allows the addition of new data manage-
ment application clients in a way that is system- and
programming language-agnostic. To control access, the
eHB uses token-based authorization, and encrypts its
data both at rest and in transit, relying on client-side
keys to decrypt the payload received from the API. For
known applications, the eHB provides subject data with
few restrictions. Client applications determine the con-
text of what information is appropriate to display to a
user, thereby enabling flexibility to meet different work-
flow and protocol requirements.
The eHB has a limited web-facing user interface that
allows for the administration of access tokens and users.
It can be managed through a comprehensive set of cre-
ate, read, update, delete (CRUD) operations exposed by
the REST API. Client applications, described in subse-
quent sections, determine the context of the request.
The client application requests resources of the eHB ser-
vice via a URL endpoint secured using transport layer
security (TLS) and, with appropriate keys and creden-
tials, can read and write data to and from the eHB
Fig. 2 The interaction between the eHB and client applications. This takes place over HTTP through CRUD (GET, POST, PUT, DELETE) operations.
Client applications (i.e., the BRP) determine the context of the information sent and received to the eHB service. Within the eHB, data is encrypted at
rest, and in transit. A query of data can only take place through the eHB software service
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service. The eHB REST service handles authorization of
the application, encrypts data and formats a response.
The actual database behind the eHB service stores only
encrypted information and would be unreadable if
accessed. This type of encryption decouples the identi-
fiers and encrypts any and all information going into the
eHB database and can be considered “privacy-by-design”
by selectively sending and granting access to information
based on context and only storing the minimum set of
information needed to stitch together a record for data
management or data query [16, 43]. The architectural
design of the eHB, illustrated in Fig. 2, utilizes web re-
quest type architecture to be a completely independent
component of the tool-kit. The eHB model is similar to
prior research in clinical informatics and the EHR.
Architecturally, the health record must have the element
of being future-proof. There is an assurance of openness
and portability through standards, flexibility and scal-
ability, semantic interoperability and acceptance from
the domain experts. In Blobel et al., the authors discuss
the fundamentals of future-proof health systems describ-
ing an “atomic component” [44]. We apply this notion
by creating an “atomic component” that must be guaran-
teed utilizing the eHB to associate the subject on the
study (as the atomic component) with their biospeci-
mens, phenotypic and genomic data.
The Biorepository Portal (BRP)
The eHB service discussed in the previous section is ex-
posed solely to external client systems through APIs and
lacks a user interface. The user-facing BRP component
provides an integrated view of multiple data manage-
ment software applications. We implement a web-based
application that uses HTTP protocols to communicate
with the eHB and external systems. The BRP allows re-
search staff to work with subject identifiers, subject re-
search data and associate specimen records. The BRP
presents the honest brokered data by integrating custom
clients using external system APIs to integrate in real-
time, the research data and patient identifiers and re-
cords. The BRP allows access via authentication utilizing
institutional identity management systems that comply
with all network access guidelines for hospital clinical
systems then limits users to specific cohorts, institutions
and data resources accessed through the portal. Figure 3
describes the layers of user access to protocols and data
sources representing applications connected to the tool
in a sudo-ER diagram.
The BRP provides context to operational tools through
clients to tools used in the context of biospecimen man-
agement. These clients are configured in the BRP as
data sources. Display options for each client can be spe-
cified by a configuration encoded in JSON [45]. JSON
formatted configuration files enable the portal to
manage the display and access of REDCap forms and
events in the data management processes based on
workflows for capturing longitudinal data. The BRP not
only relates an honest brokered subject record to exter-
nal research systems, but also relates records to each
other across systems. The following describes two imple-
mentations of external data sources; in this case a
laboratory system and a data management system. In
this case, records in these systems are linked in the BRP
to provide further context around the connection of
external research system (i.e., specimen collection record
to case report form). Figure 4 is an example of the rec-
ord listing in the BRP.
Data sources
REDCap client
The REDCap client in the BRP makes a request for the
metadata and data from a subject record stored in the
eHB and recreates the form requested utilizing the RED-
Cap API. The REDCap form client shows the patient
Medical Record Number (MRN), last name, first name
Fig. 3 Sudo ER diagram of complex relationships between users
and data sources. Users are granted access to subject records based
on protocols. Each protocol groups a list of subjects that only
authorized users can manage and are part are assigned to. Within
the walls of a protocol, there are groups of subjects that allow for
users to differentiate between institutional or site-based cohorts
(i.e., organizations). Each unique subject enrollment creates a new
record for that subject in the eHB. Within a protocol there are specific
data entry points set up as protocol data sources (e.g., a REDCap case
report form project or LIMS specimen project), and each user has
credentials to each data source. Data sources are set up as clients to
each external system represented in the BRP. In our case, we have
created data sources for two systems, REDCap and ThermoFisher
Nautilus LIMS
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and date of birth along with each customized research
data capture form. After the form record is saved, the
BRP utilizes the eHB software service to either create a
new record or modify an existing record in the REDCap
project. The REDCap project record identifier is hashed
and randomly generated without use of derived patient
information. eHB identifiers are generated utilizing the
application client key, in combination with a salted hash
value which is guaranteed to be unique [46]. Creating a
research identifier not derived from a direct patient
identifier is required when using patient data for re-
search [13]. Research identifiers are created by the con-
nected research system randomly and are not derived
from any patient information.
Adding a layer that removes the subject entity from
the REDCap projects associated with a study allows for
REDCap to facilitate user access to projects, form build-
ing, data logging, and managing a study data dictionary
[30]. The ability to supplement an entire REDCap pro-
ject(s) or form(s) as specimen annotations is accom-
plished by associating another REDCap project with a
portal project and, in turn, a subject. Our approach in-
cludes the ability to have variable numbers of projects
and nested project records per patient. There are many
variations of studies that use a variable number of RED-
Cap projects/forms and project records depending on
the need of the domain. For example, a BRP protocol
can capture demographics one time in one REDCap pro-
ject while collecting many diagnosis-type forms with
longitudinal events in another project that allows for
multiple records per subject. The eHB mediates and
stores the links between the subject entity and their pro-
ject records. Conversely, we allow for the tools to main-
tain separate cohorts of identified subjects where the
data are stored in the same REDCap project. This is par-
ticularly important for studies in which multiple
institutions are participating in sending data and speci-
mens to one data and specimen-coordinating center
(DCC/SCC). The link to REDCap records depends on
the domain and temporal requirements of a bioreposi-
tory study.
LIMS client
A key requirement in our choice of a LIMS was that it
implements an API that exposed the ability to create
new specimen records, print labels and update specimen
records with tags from external systems. The LIMS as-
signs a unique identifier to a specimen collection event,
and this identifier is associated with the subject entity in
the eHB by user input via the BRP. The BRP has a cus-
tom client that allows specimen coordinators with the
proper credentials to associate pre-labeled specimen ac-
cession kits with the subject entity. Specimen collection
kits with proper collection tubes and labels are created
prior to subject enrollment in the CHOP Biorepository
Core Facility.
The specimen coordinator then scans the barcoded
label on the kit through a LIMS client in the BRP to
associate the kit with the patient. Any downstream
laboratory work, for example; receiving, processing, ana-
lysis and storage are performed directly in the LIMS.
The laboratory technicians processing and receiving spe-
cimen kits do not see patient identifiers, only the LIMS
assigned identifier. This facilitates the longitudinal cap-




As Goble, et al., describe service oriented technology
mechanisms “…[o]nce plumbed, the data have to be
massaged and cleaned to make them fit together or
Fig. 4 Screenshot example. A screenshot from the BRP displaying identifiable data entry along the de-identified entry points for client systems’
data sources
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conform to new schema” ([36], p. 689). We meet this
requirement with ETL scripts written to integrate the
disparate and de-identified data together for scientific
use by researchers. This ETL process acts as another
application with client access to the eHB. The first
part of the ETL script uses application key-driven ac-
cess to obtain a list of subject entities on specific
protocols linked their respective research identifiers in
data management applications. This linked list is used
throughout the ETL process to join together and inte-
grate data from disparate research systems and per-
form further de-identification where required by a
study protocol. The ETL process produces data in a
relational domain model suitable for researcher query.
The ETL process is also where we integrate systems
and data that are not part of the data entry in the
BRP. If allowed by the protocol, the ETL process can
query the eHB for patient records and pull clinical
data from the health record and move it to the non-
human subject biorepository database.
Researcher query tool and non-human subject research
data resource
Integrating data sets through an ETL process is the
starting point to fully realize the research potential of an
integrated biobank. Researchers need to be able to dis-
cover available data and formulate queries for case defin-
ition and cohort creation. To enable this, we created a
query tool that allows researchers to get quick answers
to questions using available data without involving the
Institutional Review Board (IRB) because all data is de-
identified in the query tool [11]. This tool is imple-
mented using the open-source Harvest framework [32].
Harvest gives the informatics team the ability to
customize the application where necessary, but also have
an out-of-box query tool for domains of relevant data.
An example of a Harvest instance where users can
search the multi-institutional biospecimen and annota-
tion data of the CBTTC is shown in Fig. 5. This figure
shows point-and-click access to multi-dimensional and
disparate data in one place.
Fig. 5 Integrated researcher view. Integrated non-human subject data and specimen query tool built on the Harvest platform. This interface
allows for query across multiple systems in one place. The platform can be customized to allow for only certain data elements to be utilized
that depend on domain and researcher requirements. Exposed in this example are elements captures in CRFs and the LIMS. There are also links
out to genomics analysis tools
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Results and discussions
Usage results
The toolkit supports multiple biospecimen-driven re-
search studies. In these studies, the accessioning of spec-
imens and related data has grown and completely
changed in scale and volume. Figure 6 is a graph show-
ing specimen accessioning 2011 to January, 2016 for the
CBTTC. In 2012 the toolkit was adopted and the graph
illustrates the change in accession events happening
after the toolkit adoption with a varied pace of specimen
accession. This means data is available to researchers in
near real-time as accessioning happens compared to pre
2012 where data was only available as the operations
center could sort and enter data. Table 1 is a list of pro-
jects that utilize the toolkit with summary counts of sub-
jects, specimens and scientific data points as of the end
of 2015.
Operational and scientific complexity
Our methods allow for a significant amount of complex-
ity in scientific data management. With a modern, web-
service oriented architecture we abstract the subject
entity from multiple related project data in supporting
research systems, providing increased flexibility and
adaptability over comparable monolithic systems. The
tools facilitate the longitudinal collection of clinical
phenotypic data over an arbitrary time period. We also
promote asynchronous and variable collection of
specimens.
Protection of subject privacy
The architecture of the eHB helps to protect patient
privacy by limiting exposure of patient identifiers to re-
search staff. Identifiers are only available to study opera-
tions staff responsible for associating data and
specimens with subjects in the context of specific IRB
protocols. The toolkit shares implementation of security
and access controls with the connected downstream
research system (e.g., access and logging features of
REDCap). Similarly, authorization to connect LIMS spe-
cimen records to a patient record are configured with
LIMS named users, and the toolkit relies on the security
protocols exposed through the LIMS API. Researchers
only access secondary data resources that result from
Fig. 6 Usage. A graph of specimen accessioning for the CBTTC which has accessioned over 10,000 specimens to date (end of January
2016). The blue shaded area represents the sum of all specimens collected by the project
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downstream ETL and are never directly connected to
the honest broker component of the tool kit. The ability
to query the eHB allows the team to build domain spe-
cific data repositories and a web query tool limited risk
of exposing patient information.
Evolving data types and workflows
Downstream data management systems and workflows
can change project to project or as the science changes
within a project. We allow all downstream applications
do what they were designed to do without any impact
on the underlying architecture of the toolkit. The toolkit
is resilient to change, and the service-oriented architec-
ture provides hooks to incorporate additional systems,
reflecting the certainty of changing requirements, data
and workflows.
Discussion
Annotation of biospecimens with longitudinal clinical
data was the initial impetus of creating this toolkit, but
it has gone much further. The BRP and REDCap inte-
gration have enabled multiple multi-institutional biore-
pository studies, both international and national. As in
Harris et al., we enable concurrent multi-institutional
projects to be controlled by staff through a single com-
mon interface similar to other new research informatics
initiatives [30]. Exploration of HL7 for Oncology and
honest brokering is ongoing, but we have not been able
to implement these medical informatics type interchange
languages for this purpose [47]. Additionally, web
services were not built to be HIPAA compliant [9], but
we find that designing modular tools that have privacy
built in by their specific usage to be sufficient in re-
search. Further, we find the modern web architecture to
allow for the integration of the favored web tools scien-
tists are using for their research to be a novel approach.
The Children’s Brain Tumor Tissue Consortium
In Fig. 5, the data and specimen query tool of the Chil-
dren’s Brain and Tumor Tissue Consortium, is some of
the results of ambitious biorepository collaboration be-
tween six children’s hospitals. Informatics staff utilize
this set of integrated tools to support the data and
specimen-coordinating To date, the toolkit has been
central to a number of grant-funded projects focused on
next generation sequencing of biospecimens, and the
identification of causative mutations in tumors and data
integration heavy microbiologic research (See Table 1).
A researcher can quickly determine study feasibility by
reviewing available specimens and data in childhood
brain cancer research and formulate new studies focused
on finding pathways in rare cancer similar to Brastianos
et al. and Parsons et al. [27, 28]. Current efforts are fo-
cused on integration of highly dimensional genomic data
sets generated by such studies.
EMR integration
Integrating or retrieving data from the Electronic Med-
ical Record (EMR) is a growing need for users of the
toolkit. Projects originating at CHOP have been able to
Table 1 Project list this table is a list of select high-volume projects utilizing the modular tool-kit architecture described in this
manuscript that particularly integrate multiple research resources through the toolkit
Project Subjects (rounded) Specimens accessioned
(rounded)
Data integration points
The Children’s Brain Tumor Tissue Consortium 1400 9200 -Case Report Forms
-LIMS
-Cancer Genomics
University of Pennsylvania-CHOP Neurosurgery
Tissue Collaborative
1500 14,000 -Case Report Forms
-LIMS
IBD Center Biorepository Studies 177 1100 -Case Report Forms
-LIMS
-Electronic Medical Record
Center for Childhood Cancer Research 470 2200 -Case Report Forms
-LIMS
-Electronic Medical Record




The table includes the project, a rounded number of individual subjects consented to the study, specimens and the integrated data points for the
project. These numbers are rounded and are from the end of year, 2015
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take advantage of the eHB to re-identify patients for the
purpose of extracting clinical data from the CHOP
EMR. We are able to, with appropriate IRB permission,
obtain and de-identify clinical data directly from the
EMR and incorporate these data as annotations on spec-
imens and genomic data. This has proven useful in stud-
ies that require observational data such as medication at
time of specimen collection, particularly in high fre-
quency specimen collection in microbiologic research.
Genomic data integration
Continued success of biorepository-driven research re-
lies on tight integration of other scientific data points. A
primary example of this is the phenotypic and genomic
information relation. In the case of the cancer tissue
biorepository, the specific cancer genomic alterations are
specifically important to annotate specimens. We found
that allowing a researcher to query specific somatic mu-
tations from comparative analysis of sequencing the
germ-line and the tumor and find the physical speci-
mens with that mutation to be a powerful feature. We
accomplish the query of specific tumor mutations by in-
tegrating the CBioPortal into our toolkit. The CBioPortal
an open source tool developed to view cancer-based
genomic analysis data originally developed at Memorial
Sloan Kettering Cancer Center (MSKCC) is an open
access resource for exploration of multi-dimensional
cancer genomics data sets [33]. Figure 7 shows how the
integration of the CBioPortal with the clinical and speci-
men based query tool with a mix of traditional ETL and
web based endpoints. Figure 8 is a set of screen shots of
this cancer genomic data integration. This integration
point opens up a capability unavailable in previous tissue
focused biorepositories. Users can search for and view
mutations called on specimens in the local biorepository
data repository to pull a physical specimen for biological
research. Conversely, the user can search for pathways
of interest across published studies and discover if those
pathways are shown in local specimens. The user can be
moved back to the specimen request tool with the con-
text of specimens from a genomic mutation-based query.
Similarly as we continue to add scientific platforms to
the scientific side of the toolkit pertinent to domains we
are integrating with multiple commercial data manage-
ment service providers. We will extend this concept by
pushing the platform further to incorporate workflows
dedicated to the classification of pathology diagnoses
and collaborative discussion about pathology calls de-
rived from high-resolution pathology slide scans. All of
this would not be possible without a modular approach.
Fig. 7 CbioPortal – harvest integration architecture. The integrated query tool allows for a back and forth search between genes of interest and
visualization in CBioPortal, and the tool for phenotype and specimen requests. We perform this integration in a similar fashion to the other tools
in the tool-kit. We utilize a combination of constructing web endpoints and traditional ETL. The cancer genomics integration starts with a scripted
pull of mutation data via a secure database connection utilizing elements of CBioPortal’s relational data structure to store this large set of data.
Specimens known to the repository are loaded into the CBioPortal by the bioinformatics team with known specimen identifiers from the LIMS.
This creates a natural link between any granular genomic data, the specimen and ultimately the subject. URLs are constructed in the query
platform that allow for researchers to move from clinical and specimen driven queries directly to CBioPortal to visualize mutation data of interest
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Conclusions
As of January of 2016 there are 23 unique protocols/pa-
tient cohorts being managed in the Biorepository Portal
(BRP). There are over 4000 unique subject records in
the electronic honest broker (eHB), over 30,000 speci-
mens accessioned and 8 institutions participating in
various biobanking activities using this tool kit. We spe-
cifically set out to build rich annotation of biospecimens
with longitudinal clinical data; BRP/REDCap integration
for multi-institutional repositories; EMR integration; fur-
ther annotated specimens with genomic data specific to
a domain; build application hooks for experiments at the
specimen level integrated with analytic software; while
protecting privacy per the Office of Civil Rights (OCR)
and HIPAA. To meet this challenge, we created an open
source modular software toolkit that automates many
manual components of biorepository data workflows
while also protecting patient privacy. Conversely the
modular solutions allow for novel integration points for
translational research spanning clinical and genomic
data. We believe this work advances the state of the art
within the biomedical domain by moving towards mod-
ern technologies and architectures to provide transla-
tional research resources.
Availability of software
Project Name: The Biorepository Portal Toolkit
Project home page: http://www.brptoolkit.com
Code Repositories:
 Electronic Honest Broker Service: https://github.com/
chop-dbhi/ehb-service
 Electronic Honest Broker Client: https://github.com/
chop-dbhi/ehb-client
 Biorepository Portal: https://github.com/chop-dbhi/
biorepo-portal
 Data Sources: https://github.com/chop-dbhi/ehb-
datasources
Fig. 8 Specimen to cancer genomics. Screen shot of integration of the Harvest-based data and specimen query tool with a the CBioPortal for
cancer genomic visualization of a specific case
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Operating Systems: Linux
Other Requirements: Docker (optional but recommended)
License: We believe in open source software and open-
source our work. The Biorepository Toolkit and all inte-
gration work with non-proprietary systems is licensed
under BSD 2-clause License.
Restrictions to use by non-academics: None.
Ethics approval: No ethics approval was required for
this work.
A demonstration of this software is available at
http://www.brptoolkit.com. This website also contains
documentation, webinars, descriptions and pointers to
code repositories in context. Software discussed in this
paper is available on the CHOP Department of Biomedical
and Health Informatics github repository at https://
github.com/chop-dbhi. A specific implementation of the
toolkit is available through the Children’s Brain Tumor
Tissue Consortium at http://www.cbttc.org.
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